MYUNGMOON Pharm co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 16, 2022 at 02:03 am EDT
Share
MYUNGMOON Pharm co.,Ltd reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 2,836.73 million compared to negative sales of KRW 6,560.39 million a year ago. Net income was KRW 2,176.02 million compared to KRW 656.59 million a year ago. Basic earnings per share from continuing operations was KRW 64 compared to KRW 19 a year ago. Diluted earnings per share from continuing operations was KRW 64 compared to KRW 19 a year ago. Basic earnings per share was KRW 64 compared to KRW 18 a year ago.
For the six months, sales was KRW 4,163.25 million compared to KRW 3,316.65 million a year ago. Net income was KRW 3,141.31 million compared to KRW 1,274.55 million a year ago. Basic earnings per share from continuing operations was KRW 93 compared to KRW 38 a year ago. Diluted earnings per share from continuing operations was KRW 93 compared to KRW 38 a year ago. Basic earnings per share was KRW 93 compared to KRW 38 a year ago.
MyungMoon Pharm. Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceuticals. Its products include ethical (ETC) drugs and over the counter (OTC) drugs. Its ETC drugs include anesthetic agents, digestive system drugs, rheumatoid arthritis remedies, central nervous system drugs, circulatory drugs, anti-depressant agents, anti-diabetic agents, antibiotics, hormone agents, narcotics and drugs for dermatology systems. Its OTC drugs include antinauseant agents, hepatic agents, immunologic agents, antidiarrheal agents, skin external preparations, antiallergic agents, muscle relaxants, cold drugs and parasiticides. The Company is also involved in the operation golf courses. January 2, 2012, the Company completed the merger with its wholly owned subsidiary.